Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.
Investor's Business Daily on MSN50m
Novo Nordisk Surges As Next-Gen Obesity Drug OutperformsNovo Nordisk stock surged Friday after the obesity kingpin reported strong results for its next-generation weight-loss drug, amycretin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback